Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysisRahma Warsame, Angela Dispenzieri, Nelson Leung et al.|Blood Cancer Journal|2020Cited by 25
Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaPrashant Kapoor, Shaji Kumar, Morie A. Gertz et al.|Blood|2019Cited by 13
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple MyelomaShaji Kumar, Eric Wolfe, Prashant Kapoor et al.|Blood|2018Cited by 12
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosisEli Muchtar, Shaji Kumar, Morie A. Gertz et al.|Blood Advances|2022Cited by 10
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).Yucai Wang, Wei Ding, Betsy LaPlant et al.|Journal of Clinical Oncology|2024Cited by 9